updated 1/19/2011 1:18:42 PM ET 2011-01-19T18:18:42

NEW YORK, Jan. 19, 2011 (GLOBE NEWSWIRE) -- Shareholders of MELA Sciences, Inc. ("MELA" or the "Company") (Nasdaq:MELA) are reminded of the securities class action lawsuit filed against MELA and certain of its officers. The class action (Civil Action No.: 10 Civ 9024 (JFM)) pending in the Southern District of New York is on behalf of a class consisting of all persons or entities who purchased MELA securities from February 13, 2009 through November 16, 2010 (the "Class Period"). The Complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased MELA securities during the Class Period, you have until January 21, 2011 to ask the Court to appoint you as lead plaintiff for the class. A copy of the complaint can be obtained at www.pomerantzlaw.com . To discuss this action, contact Rachelle R. Boyle at rrboyle@pomlaw.com or 888.476.6529.

Throughout the Class Period, Defendants represented to the investing public that an approval of MelaFind by the United States Food and Drug Administration would be forthcoming through a series of materially false and misleading statements regarding the status of MelaFind's ongoing clinical studies, and the safety and efficacy of the Company's products. For instance, at the beginning of the Class Period, Defendants announced "positive top-line results of its pivotal trial of MelaFind, a non-invasive, point-of-care instrument to assist in the early detection of melanoma, the deadliest form of skin cancer."

In misrepresenting positive aspects of MelaFind, Defendants were able to, among other things: (a) deceive the investing public regarding MELA's business and management; (b) deceive the investing public regarding the efficacy of MelaFind and its prospects for approval; and (c) enable Defendants to sell almost $79 million of MELA's common stock to the public while in possession of material adverse non-public information about the Company.

On November 16, 2010, it was reported, in part, that MelaFind "could cause harm because of the potential for misdiagnosis," and that "FDA staff pointed to numerous problems with MELA's study of the device, called MelaFind, including a significant lack of data, and urged a new clinical trial." On this news, MELA's stock plummeted approximately 54% or $3.45 per share.

The Pomerantz Firm, with offices in New York, Chicago and Washington, D.C., is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members.

CONTACT: Rachelle R. Boyle
         Pomerantz Haudek Grossman & Gross LLP
         888-476-6529 (ext. 237)

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com